Russian government to change tender conditions for public procurement of high-priced drugs

15 September 2016

The Russian Ministry of Health is considering changing the conditions of tendering for the public procurement of high-priced drugs and vaccines, according to recent statements of an official spokesman of Veronika Skvortsova, Russia’s Minister of Health.

It is planned that changes may involve the introduction of restrictions on the participation of small companies, reports The Pharma Letter’s local correspondent.

According to the Russian legislation, currently no less than 15% of the total annual volume of drug purchases for state needs should come from small businesses (with an annual turnover of $15 million). This, according to state plans, should ensure high level of competition in the sector.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK